Clinical Research Directory
Browse clinical research sites, groups, and studies.
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Sponsor: Wake Forest University Health Sciences
Summary
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Official title: A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-04-09
Completion Date
2030-01
Last Updated
2026-02-02
Healthy Volunteers
No
Conditions
Interventions
Biospecimen samples
Buccal swabs and Blood samples will be collected throughout study.
Locations (2)
Levine Cancer Institute
Charlotte, North Carolina, United States
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States